Enjoy complimentary customisation on priority with our Enterprise License!
According to Technavio’s market research report, the global bone marrow transplant market will grow at a CAGR of more than 5% during the forecast period. The increasing federal funding in regenerative medicines is one of the key drivers that will stimulate growth in the market during the projected period. Research institutes and small companies cannot always afford the research and clinical trials of regenerative medicines because they require huge investments. The increasing importance of regenerative medicines is encouraging federal organizations to offer financial support to develop regenerative therapies. The NIH and the California Institute for Regenerative Medicine (CIRM) are some of the organizations that offer funds in the US. NIH is also providing funds for studies related to iPSC technology.
The increasing consumption of tobacco and alcohol and rising prevalence of various types of cancers is driving the market for bone marrow transplant in EMEA. Bone marrow registry helps to improve the scarcity of donor and better genetical match. The increase in bone marrow registry will boost the number of donors across the regions and result in better medical logistics and storage.
The global bone marrow transplant market is characterized by the presence of many key vendors. These vendors compete against each other based on factors such as inorganic strategies, pricing strategies, expansion of collection centers. The increased inorganic growth strategies and expansion of collection centers will strengthen the competitive scenario of the market.
Key vendors in this market are -
Other prominent vendors in the market include Athersys, Beike Biotechnology, BioTime, bluebird bio, Caladrius, Cellular Biomedicine Group, Cellular Dynamics International, Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, CORESTEM, Gamida Cell, Global Stem Cells Group, Hemostemix, Histocell, Mesoblast, TiGenix, and Translational Biosciences.
An autologous bone marrow transplant is highly preferred by surgeons as they involve fewer complications. The segment will continue to grow during the predicted period due to the rising prevalence of diseases such as Hodgkin and non-Hodgkin lymphomas, multiple myeloma, and autoimmune diseases.
Multiple myeloma is a type of cancer formed by malignant plasma cells. The segment will grow from 2017 to 2021 because autologous bone marrow transplants are highly preferred over allogeneic bone marrow transplants for the treatment of multiple myeloma.
Technavio also offers customization on reports based on specific client requirement
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Market segmentation by transplant type
PART 07: Market segmentation by indication
PART 08: Geographical segmentation
PART 09: Decision framework
PART 10: Drivers and challenges
PART 11: Market trends
PART 12: Vendor landscape
PART 13: Key vendor analysis
PART 14: Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.